Astellas Pharma
Update in progress4503.T (Tokyo)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryDrug Manufacturers - General
Astellas Pharma Inc. is a global pharmaceutical company that develops, markets, imports and exports medicines in Japan and worldwide. It offers XTANDI (prostate cancer), XOSPATA (AML), VYLOY (gastric cancer), PADCEV (metastatic urothelial cancer), VEOZAH (vasomotor symptoms), IZERVAY (geographic atrophy), EVRENZO (anemia in CKD), Betanis/Myrabetriq/BETMIGA (overactive bladder), and Prograf immunosuppressant. It partners with xFOREST Therapeutics and Roche Diabetes Care Japan. Founded 1923, headquartered in Chuo, Japan.
Company score
- Sentiment
- 1.85
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.75
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 2.17
- Governance
- 0.52
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 1.01
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 1.43
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketTokyo (JPX)
- LocationJapan
- CEOMr. Naoki Okamura BSc
- Founded1923
- Employees14,099
- Websitewww.astellas.com
Identifiers
- ISINJP3942400007